Who Prioritizes Innovation? R&D Spending Compared for AstraZeneca PLC and Arrowhead Pharmaceuticals, Inc.

Comparing R&D Priorities: AstraZeneca vs. Arrowhead

__timestampArrowhead Pharmaceuticals, Inc.AstraZeneca PLC
Wednesday, January 1, 2014231380505579000000
Thursday, January 1, 2015574101475997000000
Friday, January 1, 2016414544525890000000
Sunday, January 1, 2017316902985757000000
Monday, January 1, 2018529685055932000000
Tuesday, January 1, 2019810486865958000000
Wednesday, January 1, 20201288749795991000000
Friday, January 1, 20212063420009736000000
Saturday, January 1, 20222973070009762000000
Sunday, January 1, 202335318800010935000000
Monday, January 1, 202450587000013583000000
Loading chart...

In pursuit of knowledge

Innovation in Pharmaceuticals: A Comparative Analysis

In the ever-evolving world of pharmaceuticals, research and development (R&D) spending is a key indicator of a company's commitment to innovation. AstraZeneca PLC and Arrowhead Pharmaceuticals, Inc. are two prominent players in this field, each with distinct strategies. Over the past decade, AstraZeneca has consistently invested heavily in R&D, with expenditures peaking at approximately $10.9 billion in 2023, marking a 96% increase from 2014. In contrast, Arrowhead Pharmaceuticals, while smaller in scale, has shown a remarkable growth trajectory, with R&D spending surging by over 2,000% from 2014 to 2024. This stark difference highlights AstraZeneca's established presence and Arrowhead's aggressive growth strategy. The data for 2024 is incomplete for AstraZeneca, but the trend suggests a continued focus on innovation. These insights underscore the dynamic nature of the pharmaceutical industry and the varied approaches companies take to drive progress.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025